

## Appendix 2:

Baseline information of the anticancer medicines included in the NRDL by 2016–2021 negotiations

Generic Name	Manufacturer	Reimbursement indications	
2016			
Gefitinib	AstraZeneca	NSCLC	Moved into routine list in 2017
Icotinib	Beta Pharma	NSCLC	Moved into routine list in 2017
2017			
Rituximab	Roche	Lymphoma	Moved into routine list in 2019
Trastuzumab	Roche	Breast Cancer; Gastric Cancer	Re-negotiated in 2019 ✓ Moved into routine list in 2021
Bevacizumab	Roche	CRC; NSCLC; HCC *; rGBM *	Re-negotiated in 2019 ✓ Moved into routine list in 2021
Nimotuzumab	Biotech	Nasopharyngeal Carcinoma	Re-negotiated in 2019 and 2021 ✓
Erlotinib	Roche	NSCLC	Re-negotiated in 2019 ✓ Moved into routine list in 2021
Sorafenib	Bayer	HCC; RCC; Thyroid Cancer	Re-negotiated in 2019 ✓ Moved into routine list in 2021
Lapatinib	GSK	Breast Cancer	Re-negotiated in 2019 (Failed)
Apatinib	Hengrui Medicine	Gastric Cancer; HCC *	Re-negotiated in 2019 and 2021 ✓
Bortezomib	Xi'an Janssen	Multiple Myeloma; MCL	Moved into routine list in 2019
Recombinant Human Endostatin	Shandong Simcere	NSCLC	Re-negotiated in 2019 and 2021 ✓

Chidamide	Chipscreen Biosciences	Peripheral T-cell Lymphoma	Re-negotiated in 2019 and 2021 ✓
Abiraterone	Xi'an Janssen	Prostate Cancer	Moved into routine list in 2019
Fulvestrant	AstraZeneca	Breast Cancer	Re-negotiated in 2019 (Failed) Moved into routine list in 2020
Everolimus	Novartis	RCC; pNET; TSC-AML; Subependymal giant cell astrocytoma *	Re-negotiated in 2019 and 2021 ✓
Lenalidomide	Celgene	Multiple Myeloma	Moved into routine list in 2019
Compound Realgar Natural Indigo Tablets※	Yifan Pharma	Acute Promyelocytic Leukemia	Re-negotiated in 2019 ✓
Shenyi Capsule※	Jilin Yatai	Adjuvant Therapy	Re-negotiated in 2019 ✓
Astragalus polysaccharide Injection※	Tianjin Sainuo	Adjuvant Therapy	Re-negotiated in 2019 ✓
2018			
Osimertinib	AstraZeneca	NSCLC	Re-negotiated in 2020 ✓
Ceritinib	Novartis	NSCLC	Re-negotiated in 2020 ✓
Afatinib	Boehringer Ingelheim	NSCLC	Moved into routine list in 2020
Crizotinib	Pfizer	NSCLC	Re-negotiated in 2020 ✓
Anlotinib	Chiatai Tianqing	NSCLC; Soft Tissue Sarcoma *	Re-negotiated in 2020 ✓
Vemurafenib	Roche	Melanoma	Re-negotiated in 2020 ✓
Cetuximab	Merck	CRC; Head & Neck Cancer *	Re-negotiated in 2020 and 2021 ✓
Regorafenib	Bayer	HCC; CRC; GIST	Re-negotiated in 2020 ✓

Pazopanib	Novartis	RCC	Re-negotiated in 2020 ✓
Sunitinib	Pfizer	RCC; GIST; pNET	Moved into routine list in 2020
Axitinib	Pfizer	RCC	Re-negotiated in 2020 ✓
Octreotide Microspheres	Novartis	GEP-NET	Re-negotiated in 2020 ✓
Ibrutinib	Jassen	MCL; CLL/SLL	Re-negotiated in 2020 ✓
Ixazomib	Takeda	Multiple Myeloma	Re-negotiated in 2020 ✓
Nilotinib	Novartis	MCL	Re-negotiated in 2020 ✓
Azacitidine	Celgene/BeiGene	MDS; CMML; AML	Moved into routine list in 2020
Pegaspargase	Hengrui Medicine	Acute Lymphocytic Leukemia	Re-negotiated in 2020 ✓
2019			
Alectinib	Roche	NSCLC	Re-negotiated in 2021 ✓
Fruquintinib	Chi-Med	CRC	Re-negotiated in 2021 ✓
Raltitrexed	Chiatai Tianqing	CRC	Moved into routine list in 2021
Olaparib	AstraZeneca	Ovarian Cancer, Fallopian Tube Cancer; Primary Peritoneal Cancer	Re-negotiated in 2021 ✓
Pyrotinib	Hengrui Medicine	Breast Cancer	Re-negotiated in 2021 ✓
Pertuzumab	Roche	Breast Cancer	Re-negotiated in 2021 ✓
Sintilimab	Innovent	Hodgkin's Lymphoma; NSCLC * ; HCC *	Re-negotiated in 2021 ✓
Ruxolitinib	Novartis	PMF; PPV-MF; PET-MF	Re-negotiated in 2021 ✓
Mecapegfilgrastim	Hengrui Medicine	Adjuvant therapy	Re-negotiated in 2021 ✓
Shidaoping San※	Shanxi IOK Pharma	Esophageal Cancer	Re-negotiated in 2021 ✓
2020			

Niraparib	Zai Lab	Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer	
Enzalutamide	Astellas	Prostate Cancer	
Flumatinib	Hansoh Pharma	Myelogenous Leukemia, CML	
Tislelizumab	BeiGene	Hodgkin's Lymphoma, Urothelial Carcinoma; NSCLC * ; HCC *	Re-negotiated in 2021 ✓
Almonertinib	Hansoh Pharma	NSCLC	
Denosumab	Amgen	Giant Cell Tumor of the Bone	
Lenvatinib	Eisai	HCC	
Toripalimab	Junshi Biosciences	Melanoma; Nasopharyngeal Carcinoma * ; Urothelial Carcinoma *	Re-negotiated in 2021 ✓
Camrelizumab	Hengrui Medicine	HCC; NSCLC; Esophagus Cancer; Hodgkin's Lymphoma	
Trametinib	GSK	Melanoma	
Dabrafenib	GSK	Melanoma	
Inetetamab	Sunshine Guojian	Breast Cancer	
Zanubrutinib	BeiGene	MCL,CLL/SLL; Waldenstrom's macroglobulinemia *	Re-negotiated in 2021 ✓
Paclitaxel Liposome Injection	Luye Pharma	NSCLC; Breast Cancer; Ovarian Cancer	
Oxaliplatin and Mannitol Injection		CRC	Direct included generic with volume based pricing

Fulvestrant		Breast Cancer	Direct included generic with volume based pricing
Paclitaxel Injection (albumin-bound)		Breast Cancer	Direct included generic with volume based pricing
2021			
Donafenib	Zelgen Biopharma	HCC	
Ensartinib	Betta Pharma	NSCLC	
Furmonertinib	Allist	NSCLC	
Dacomitinib	Pfizer	NSCLC	
Orelabrutinib	InnoCare	MCL; CLL/SLL	
Obinutuzumab	Roche	Follicular Lymphoma	
Fluzoparib	Hengrui Medicine	Ovarian Cancer	
Pamiparib	BeiGene	Ovarian Cancer	
Abemaciclib	Eli Lilly	Breast Cancer	
Eribulin mesylate	Eisai	Breast Cancer	
Neratinib	CANbridge	Breast Cancer	
Sulfatinib	Chi-Med	Neuroendocrine Tumor	
Daratumumab	Janssen	Multiple Myeloma	
Pomalidomide	CTTQ	Multiple Myeloma	
Apalutamide	Janssen	Prostate Cancer	
Darolutamide	Bayer	Prostate Cancer	
Disitamab vedotin	RemeGen	Gastric Cancer	

Bendamustine		Tumor	Direct included generic with volume based pricing
--------------	--	-------	---

\* indicates expanded in the renewal negotiation; ※ refers to Chinese Patent Medicine; ✓ means success in negotiation/re-negotiation

**Abbreviation:**

**AML:** acute myelogenous leukemia, **CLL:** chronic lymphocytic leukemia, **CMML:** chronic myelomonocytic leukemia, **CRC:** colorectal cancer,

**GEP-NET:** gastroenteropancreatic neuroendocrine tumor, **GIST:** gastrointestinal stromal tumors, **HCC:** hepatocellular carcinoma, **MCL:** Mantle Cell

Lymphoma, **MDS:** myelodysplastic syndromes, **NSCLC:** non-small cell lung cancer, **PET-MF:** post-essential thrombocythemia myelofibrosis, **PMF:**

primary myelofibrosis, **pNET:** Pancreatic neuroendocrine tumor, **PPV-MF:** post-polycythemia vera myelofibrosis, **RCC:** renal cell carcinoma, **rGBM:**

recurrent glioblastoma, **SLL:** small lymphocytic lymphoma, **TSC-AML:** Tuberous Sclerosis Complex-associated Angiomyolipoma